The Cancer Surveillance and Outcomes Research Team at the University of Michigan Comprehensive Cancer Center recently developed an interactive online tool to help patients with breast cancer understand their treatment options more fully.
The Cancer Surveillance and Outcomes Research Team at the University of Michigan Comprehensive Cancer Center recently developed an interactive online tool to help patients with breast cancer understand their treatment options more fully.
“Knowledge is a key component of decision making, and yet it’s consistently low even among patients who have received treatment. We need better tools to make these decisions more informed,” Sarah T. Hawley, PhD, MPH, professor of internal medicine at Michigan Medicine, said in a statement.
According to a new study published in the Journal of Clinical Oncology, when compared with a static informational website, patients who used the interactive tool had higher knowledge and felt more prepared to make a treatment decision.
The study included 537 patients with newly diagnosed early-stage breast cancer from multiple practices spread throughout 4 states. The participating patients were randomized to view a tailored, interactive tool called “iCanDecide,” or to view similar information on a static website. Participants were then surveyed about 5 weeks later (496 completed the survey), after making their treatment decision.
The results showed that 61% of patients who used the interactive online tool had a high knowledge of treatment options compared with 42% of patients who viewed the static material. When asked if they felt prepared to make a treatment decision, 50% of patients who used the interactive tool responded that they felt prepared, compared with 33% of patients that viewed the static material.
“Instead of throwing the information on the website and hoping patients would figure it out, we gave them the bullet point fact, asked a question to see if they understood, and then allowed them to drill down and look at more detailed information. They couldn’t just bounce around. They had to go through it in a linear fashion,” said Hawley.
The interactive tool also assessed patients’ values through a series of hypothetical scenarios. At the end of the assessment, each patient received a personalized bar graphic that showed how their preferences matched to treatments. For example, if they valued keeping their natural breast, the lumpectomy bar would be higher.
“The values clarification is important. If you don’t combine the knowledge and the values, you get people making values-based choices that may not be fully informed,” said Hawley.
The researchers plan to refine the tool further to enhance the timing of decision tools and assessing patient values.
References
Hawley ST, Li Y, An LC, et al. Improving breast cancer surgical treatment decision making: the iCanDecide randomized clinical trial. J Clin Oncol. doi: 10.1200/JCO.2017.74.8442. Published online ahead of print January 24, 2018.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More